Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19788362 | 1.00 | KDR (0.32) | KDRADORA2BCNR2KMT2A | |
| SCHEMBL21719823 | 1.00 | KDR (0.32) | KDRADORA2BCNR2KMT2A | |
| SCHEMBL23709527 | 0.98 | KDR (0.31) | KDRADORA2B | |
| SCHEMBL22024734 | 0.97 | KMT2A (0.30) | KMT2A | |
| SCHEMBL22023802 | 0.86 | CNR2 (0.36) | CNR2 | |
| SCHEMBL22023933 | 0.79 | CNR1 (0.30) | CNR2 | |
| SCHEMBL23502540 | 0.76 | CNR2 (0.34) | CNR2 | |
| SCHEMBL23502537 | 0.76 | CNR2 (0.34) | CNR2 | |
| SCHEMBL26018134 | 0.74 | GPR84 (0.33) | ADORA2BCNR2 | |
| SCHEMBL23845817 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | ENANTA PHARMACEUTICALS, INC. | 2023-10-31 | — | — | US | disclosed |
| US-20230038124-A1 | NOVEL SUBSTITUTED CONDENSED RING COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2023-02-09 | — | — | US | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802125-B2 | Functionalized heterocyclic compounds as antiviral agents | HAVCR2, HDGF, HCCS | KDR 3916/4885ADORA2B 2003/4885CNR2 3458/4885 |
| US-20230038124-A1 | NOVEL SUBSTITUTED CONDENSED RING COMPOUND | CYP51A1, HDAC11, MMP9 | KDR 4791/4885ADORA2B 4515/4885CNR2 4103/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | KDR 3782/4885ADORA2B 1928/4885CNR2 2902/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | KDR 3782/4885ADORA2B 1928/4885CNR2 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.